Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: yosarian_2 who wrote (4465)	1/17/2017 9:20:39 PM
From: kenyonn	Respond to of 4474

Great to see both of you held on until the end, GA and Yo. I think both of you may go all the way back to the Raging Bull board, but maybe I'm wrong. I bought my first Ariad shares in 1995. What a ride. I wish you all the best.

To: yosarian_2 who wrote (4465)	1/19/2017 11:51:07 AM
From: GregorioAllegri	Respond to of 4474

AML: I am certainly not as well informed as your friend's oncology doc... and maybe not as well informed as you... Try this: www.amlglobalportal.com Look through clinicaltrials.gov searching "Acute myeloid leukemia" Make sure she gets a mutational profile of her AML. Like NSCLC, it is actually a complex of several diseases with varying genetic causes. If lucky, there may be a targeted therapy trial for her to join or use off-label (e.g. ponatinib vs. certain mutant forms of FLT3.) If there are no targeted therapies, you might consider PD-1 checkpoint inhibitors (OPDIVO, KEYTRUDA) ncbi.nlm.nih.gov PD-1 inhibitors might be a better choice than targeted therapies if the disease is quite advanced and they tend to work, when they do, against almost all mutational types. It amazes me how big pharma keeps trying with chemo drugs, but that is only my opinion. Their effectiveness versus this disease appears, after a very superficial investigation, to be limited. Take with a grain of salt. I am a computational chemist, not an oncology doc. ga